Study of giredestrant for early hormone-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies how patients with early-stage, hormone-positive (ER+) breast cancer feel and how well they tolerate a new oral medication, giredestrant, during treatment. It aims to help improve quality of life and manage side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage breast cancer that is estrogen receptor positive (ER+) and HER2-negative.
- You have already had surgery to remove the tumor and some lymph nodes.
- You are on a stable treatment plan: your physical condition is reasonably good (able to take care of yourself and be up and about).
- You meet basic health requirements for organ function.
- If you are a man or a pre/perimenopausal woman, you must receive a medication to lower estrogen (GnRH agonist).
- You have not used the study drug (giredestrant) or similar experimental hormone drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
This expanded access program provides an experimental drug called giredestrant to people with ER-positive, HER2-negative breast cancer. It's designed for those with early-stage disease at reasonable risk of recurrence, or those with advanced cancer whose disease has progressed on standard hormone therapy plus a CDK4/6 inhibitor.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests a new drug (GDC-4198) combined with standard hormone therapies for people with advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative. It may help by improving the effectiveness of hormone therapy and slowing cancer growth.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.